Dr. Ammar Consulting Center

11/10/2025

Benefits of vitamin Aiif in autoimmune diseases
Autoimmune diseases are disorders where the body's immune system mistakenly attacks healthy tissues, resulting in over 100 different conditions. Common examples include Type 1 Diabetes, which affects the pancreas; Rheumatoid Arthritis, which targets the joints; Multiple Sclerosis, impacting the nervous system; and Systemic Lupus Erythematosus (Lupus), a widespread condition affecting various organs. Other examples include Celiac disease, Graves' disease, Hashimoto's thyroiditis, Crohn's disease, psoriasis, and Scleroderma.

05/13/2024

الاصابة الحزام الناري على الساق اليمنى

05/13/2024

04/12/2024

لبشرة نضرة

04/12/2024

لبشرة نقية كبشرة الأطفال بخلاصة الأعشاب من الطبيعة☘

03/25/2022

Lung cancer
PATIENTS AND METHODS

We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-mutated lung cancer who received EGFR-tyrosine kinase inhibitors (TKIs) between 2012 and 2019. The primary outcome was the incidence of HT. The secondary outcome was treatment efficacy in patients with HT.

RESULTS

In total, 6356 patients were enrolled. In 2624 patients, the histological type was proven by rebiopsy after acquiring resistance to EGFR-TKIs. Among them, 74 patients had HT (incidence rate: 2.8% [95% confidence interval: 2.3%-3.5%]). The median progression-free survival after EGFR-TKIs and first-line therapy after confirming HT was 10.4 and 4.4 months, respectively, which was not significantly different between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Overall survival after confirming HT was 12.2 months. Twenty-seven patients received immune checkpoint inhibitors: 6 and 21 received immune checkpoint inhibitors before and after confirming HT, respectively. No patients achieved 1-year progression-free survival. The median progression-free survival after immune checkpoint inhibitor therapy after confirming HT was 1.6 months.

CONCLUSION

HT occurred in approximately 3% of EGFR-mutated patients who developed resistance to EGFR-TKIs. Cytotoxic agents are likely to be effective in patients with HT. However, the therapeutic effectiveness of immune checkpoint inhibitors was limited in these patients. Given the rarity of HT and absence of prospective trials, our findings are important to inform the treatment of these patients.

06/11/2020

وجبات صحية

05/04/2020